Vascular endothelial growth factor activates MAP kinase and enhances collagen synthesis in human mesangial cells

Tetsuro Amemiya, Hiroyuki Sasamura, Mizuo Mifune, Yudai Kitamura, Junichi Hirahashi, Matsuhiko Hayashi, Takao Saruta

Research output: Contribution to journalArticle

61 Citations (Scopus)

Abstract

Background. Vascular endothelial growth factor (VEGF) is an endothelial mitogen that is constitutively expressed in normal human glomeruli, but its role in the kidney is still unclear. In this study, we examined the effects of VEGF on human mesangial cells (HMCs). Methods and Results. Reverse transcription-polymerase chain reaction analysis demonstrated the presence of VEGF receptor mRNA (flt-1 and KDR) in HMCs. The treatment of HMCs with VEGF did not cause a change in 3H-thymidine incorporation or cell numbers. In contrast, VEGF caused a dose- and time-dependent increase in collagen synthesis, with threefold to fivefold increases in both cell-associated and secreted collagen synthesis seen after treatment with 200 ng/ml VEGF. The effects of VEGF were attenuated by treatment of HMCs with the tyrosine kinase inhibitor herbimycin A or the MEK inhibitor PD 98059, but not with the protein kinase C (PKC) inhibitor chelerythrine. VEGF treatment also caused a marked increase in p42/p44 mitogen-activated protein kinase (MAPK) activity, but had no significant effect on HMC superoxide production. Finally, an increase in collagen synthesis was also seen in rat mesangial cells treated with VEGF. Conclusions. These results suggest that VEGF is not a mitogenic signal in HMCs, but may be involved in the regulation of the mesangial matrix in humans by a MAPK-dependent mechanism.

Original languageEnglish
Pages (from-to)2055-2063
Number of pages9
JournalKidney International
Volume56
Issue number6
DOIs
Publication statusPublished - 1999

Fingerprint

Mesangial Cells
Vascular Endothelial Growth Factor A
Phosphotransferases
Collagen
Vascular Endothelial Growth Factor Receptor
Protein C Inhibitor
Mitogen-Activated Protein Kinase 1
Mitogen-Activated Protein Kinase Kinases
Protein Kinase Inhibitors
Mitogen-Activated Protein Kinases
Mitogens
Superoxides
Protein-Tyrosine Kinases
Thymidine
Protein Kinase C
Reverse Transcription
Cell Count
Kidney
Polymerase Chain Reaction
Messenger RNA

Keywords

  • Angiogenesis
  • Injury
  • Mesangial matrix
  • Mitogen activated protein kinase
  • VEGF

ASJC Scopus subject areas

  • Nephrology

Cite this

Vascular endothelial growth factor activates MAP kinase and enhances collagen synthesis in human mesangial cells. / Amemiya, Tetsuro; Sasamura, Hiroyuki; Mifune, Mizuo; Kitamura, Yudai; Hirahashi, Junichi; Hayashi, Matsuhiko; Saruta, Takao.

In: Kidney International, Vol. 56, No. 6, 1999, p. 2055-2063.

Research output: Contribution to journalArticle

Amemiya, Tetsuro ; Sasamura, Hiroyuki ; Mifune, Mizuo ; Kitamura, Yudai ; Hirahashi, Junichi ; Hayashi, Matsuhiko ; Saruta, Takao. / Vascular endothelial growth factor activates MAP kinase and enhances collagen synthesis in human mesangial cells. In: Kidney International. 1999 ; Vol. 56, No. 6. pp. 2055-2063.
@article{2e62c2f400114a98a78fb6fae5a28968,
title = "Vascular endothelial growth factor activates MAP kinase and enhances collagen synthesis in human mesangial cells",
abstract = "Background. Vascular endothelial growth factor (VEGF) is an endothelial mitogen that is constitutively expressed in normal human glomeruli, but its role in the kidney is still unclear. In this study, we examined the effects of VEGF on human mesangial cells (HMCs). Methods and Results. Reverse transcription-polymerase chain reaction analysis demonstrated the presence of VEGF receptor mRNA (flt-1 and KDR) in HMCs. The treatment of HMCs with VEGF did not cause a change in 3H-thymidine incorporation or cell numbers. In contrast, VEGF caused a dose- and time-dependent increase in collagen synthesis, with threefold to fivefold increases in both cell-associated and secreted collagen synthesis seen after treatment with 200 ng/ml VEGF. The effects of VEGF were attenuated by treatment of HMCs with the tyrosine kinase inhibitor herbimycin A or the MEK inhibitor PD 98059, but not with the protein kinase C (PKC) inhibitor chelerythrine. VEGF treatment also caused a marked increase in p42/p44 mitogen-activated protein kinase (MAPK) activity, but had no significant effect on HMC superoxide production. Finally, an increase in collagen synthesis was also seen in rat mesangial cells treated with VEGF. Conclusions. These results suggest that VEGF is not a mitogenic signal in HMCs, but may be involved in the regulation of the mesangial matrix in humans by a MAPK-dependent mechanism.",
keywords = "Angiogenesis, Injury, Mesangial matrix, Mitogen activated protein kinase, VEGF",
author = "Tetsuro Amemiya and Hiroyuki Sasamura and Mizuo Mifune and Yudai Kitamura and Junichi Hirahashi and Matsuhiko Hayashi and Takao Saruta",
year = "1999",
doi = "10.1046/j.1523-1755.1999.00796.x",
language = "English",
volume = "56",
pages = "2055--2063",
journal = "Kidney International",
issn = "0085-2538",
publisher = "Nature Publishing Group",
number = "6",

}

TY - JOUR

T1 - Vascular endothelial growth factor activates MAP kinase and enhances collagen synthesis in human mesangial cells

AU - Amemiya, Tetsuro

AU - Sasamura, Hiroyuki

AU - Mifune, Mizuo

AU - Kitamura, Yudai

AU - Hirahashi, Junichi

AU - Hayashi, Matsuhiko

AU - Saruta, Takao

PY - 1999

Y1 - 1999

N2 - Background. Vascular endothelial growth factor (VEGF) is an endothelial mitogen that is constitutively expressed in normal human glomeruli, but its role in the kidney is still unclear. In this study, we examined the effects of VEGF on human mesangial cells (HMCs). Methods and Results. Reverse transcription-polymerase chain reaction analysis demonstrated the presence of VEGF receptor mRNA (flt-1 and KDR) in HMCs. The treatment of HMCs with VEGF did not cause a change in 3H-thymidine incorporation or cell numbers. In contrast, VEGF caused a dose- and time-dependent increase in collagen synthesis, with threefold to fivefold increases in both cell-associated and secreted collagen synthesis seen after treatment with 200 ng/ml VEGF. The effects of VEGF were attenuated by treatment of HMCs with the tyrosine kinase inhibitor herbimycin A or the MEK inhibitor PD 98059, but not with the protein kinase C (PKC) inhibitor chelerythrine. VEGF treatment also caused a marked increase in p42/p44 mitogen-activated protein kinase (MAPK) activity, but had no significant effect on HMC superoxide production. Finally, an increase in collagen synthesis was also seen in rat mesangial cells treated with VEGF. Conclusions. These results suggest that VEGF is not a mitogenic signal in HMCs, but may be involved in the regulation of the mesangial matrix in humans by a MAPK-dependent mechanism.

AB - Background. Vascular endothelial growth factor (VEGF) is an endothelial mitogen that is constitutively expressed in normal human glomeruli, but its role in the kidney is still unclear. In this study, we examined the effects of VEGF on human mesangial cells (HMCs). Methods and Results. Reverse transcription-polymerase chain reaction analysis demonstrated the presence of VEGF receptor mRNA (flt-1 and KDR) in HMCs. The treatment of HMCs with VEGF did not cause a change in 3H-thymidine incorporation or cell numbers. In contrast, VEGF caused a dose- and time-dependent increase in collagen synthesis, with threefold to fivefold increases in both cell-associated and secreted collagen synthesis seen after treatment with 200 ng/ml VEGF. The effects of VEGF were attenuated by treatment of HMCs with the tyrosine kinase inhibitor herbimycin A or the MEK inhibitor PD 98059, but not with the protein kinase C (PKC) inhibitor chelerythrine. VEGF treatment also caused a marked increase in p42/p44 mitogen-activated protein kinase (MAPK) activity, but had no significant effect on HMC superoxide production. Finally, an increase in collagen synthesis was also seen in rat mesangial cells treated with VEGF. Conclusions. These results suggest that VEGF is not a mitogenic signal in HMCs, but may be involved in the regulation of the mesangial matrix in humans by a MAPK-dependent mechanism.

KW - Angiogenesis

KW - Injury

KW - Mesangial matrix

KW - Mitogen activated protein kinase

KW - VEGF

UR - http://www.scopus.com/inward/record.url?scp=0033405953&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0033405953&partnerID=8YFLogxK

U2 - 10.1046/j.1523-1755.1999.00796.x

DO - 10.1046/j.1523-1755.1999.00796.x

M3 - Article

C2 - 10594781

AN - SCOPUS:0033405953

VL - 56

SP - 2055

EP - 2063

JO - Kidney International

JF - Kidney International

SN - 0085-2538

IS - 6

ER -